ACCRUED EXPENSES AND LONG-TERM LIABILITIES

9 Months Ended

Sep. 30, 2021

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND LONG-TERM LIABILITIES

9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020:

	September 30, 2021		December 31, 2020
	(unaudited)
Accrued royalties	$	3,572	$	2,710
Upfront Medicare payment		-		2,066
Operating lease liabilities		1,030		1,027
All others		1,056		1,182
Accrued professional fees		931		854
Unclaimed property		565		565
Contingent consideration		473		398
Accrued pharma services invoices		438		108
Taxes payable		248		334
Accrued lab costs - diagnostics		514		161
Financing lease liabilities		98		177
ESPP payable		37		108
Accrued sales and marketing - diagnostics		41		51
Deferred revenue		40		54
Total other accrued expenses	$	9,043	$	9,795

Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020:

	September 30, 2021		December 31, 2020
	(unaudited)
Uncertain tax positions	$	4,517	$	4,342
Warrant liability		158		21
Financing lease liabilities		75		138
Deferred revenue		18		136
Total other long-term liabilities	$	4,768	$	4,637